Browsing by Author "El-Refaei M.F."

Now showing 1 - 3 of 3

Antioxidant and apoptotic effects of caffeic acid phenethyl ester induced marked inhibition on human breast cancer cell line
(2011) El-Refaei M.F.; El-Naa M.M.; Department of Molecular Biology; Genetic Engineering and Biotechnology Institute; Menoufiya University; Egypt; Department of Pharmacology and Toxicology; Faculty of Pharmacy; October University for Modern Sciences and Arts; Egypt
Cancer is a disease that is marked by high cell proliferation and metastasis which remains incurable even now. The present study aims at investigating the anti-proliferative and apoptotic effects of Caffeic Acid Phenethyl Ester (CAPE) against human carcinogenesis. This fact was established in vitro by our assessment of a ZR-75-1 human breast cancer cell line. Present data showed that 15 ?M CAPE induced a significant inhibition of cell viability after 48 h (nearly 50%). Cell death was characterized by morphology and chromatin condensation changes, of a typical apoptosis. Moreover, there was a scavenging reduction activity in vitro towards both nitric oxide (>47%) and superoxide dismutase reduction (169.3�3.7 ?U L-1). In addition, malondialdehyde was non significantly inhibited compared with untreated tumor cells. The CAPE has significant inhibitory and anti-proliferative effects on tumor cancer cells in vitro. This inhibition may be related to its antioxidant effects and achieved throughout its apoptotic effect. These findings provide the possibility for the future use of CAPE in human clinical trials therapy. � 2011 Academic Journals Inc.
In-vivo antioxidant and anti-inflammatory activity of rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists in animal model of bronchial asthma.
(Blackwell Publishing Ltd, 2015) El-Naa M.M.; El-Refaei M.F.; Nasif W.A.; Abduljawad S.H.; El-Brairy A.I.; El-Readi M.Z.; Department of Pharmacology and Toxicology; Faculty of Pharmacy; October University for Modern Sciences and Arts; 6 October City; Egypt; Molecular Biology Department; Institute of Genetic Engineering and Biotechnology; Sadat City University; Sadat City; Egypt; Department of Biochemistry; Faculty of Pharmacy; Al-Azhar University; Assiut; Egypt; Department of Biochemistry; Faculty of Medicine; Umm Al-Qura University; Makkah; Saudi Arabia; Department of Food Sciences; Faculty of Family Science; Taibah University; Al Madinah Al-Munawarah; Saudi Arabia; Department of Clinical Biochemistry; Faculty of Medicine; Umm Al-Qura University; P.O. Box 13174; Abdia; Makkah; 21955; Saudi Arabia
Objectives Peroxisome proliferator activated receptor-gamma (PPAR-?) has been shown to play an important role in the control of immunological and inflammatory responses. This study aims at investigating the potential role of rosiglitazone, a strong PPAR-? agonist in a murine model of bronchial asthma. Methods Adult male Guinea pigs were administered ovalbumin 100 mg/kg subcutaneous (SC) and 100 mg/kg intraperitoneal (IP). Treatment with rosiglitazone [5 mg/kg/day, per oral (PO)] was assessed for 21 days. On day 21, the animals were challenged with the same dose of ovalbumin. The forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC), FEV1/FVC, was measured using a spirometer to diagnosis lung obstruction. Serum levels of interleukin-5 (IL-5) and immunoglobulin E (IgE) were assessed. The activity of superoxide dismutase (SOD) and catalase and the level of reduced glutathione (GSH) were determined in lung tissue homogenates. Key findings Our results demonstrated that treatment with rosiglitazone resulted in a statistically significant improvement in lung function and histopathological features. Significant decrease in the serum levels of IL-5 and IgE were observed. The activity of SOD and catalase as well as the GSH level were significantly increased in the lung tissues of treated animals compared with untreated asthmatic animals. Serum IgE concentrations and IL-5 levels were directly correlated to each other and inversely correlated to the SOD, GSH and catalase levels in the all studied Guinea pigs. Conclusions Our results provide evidence that the PPAR-? agonist rosiglitazone may have potential in the development of therapies for bronchial asthma. 2015 Royal Pharmaceutical Society.
Inhibitory effect of caffeic acid phenethyl ester on mice bearing tumor involving angiostatic and apoptotic activities
(2010) El-Refaei M.F.; El-Naa M.M.; Molecular Biology Department; Genetic Engineering and Biotechnology Institute; Menoufiya University; Egypt; Department of Pharmacology and Toxicology; Faculty of Pharmacy; October University for Modern Sciences and Arts; Egypt
This study aims at investigating the anti-tumor effect of caffeic acid phenethyl ester (CAPE) against animal carcinogenesis. In order to substantiate this fact implanted tumor Ehrlich carcinoma cells were assessed in vivo to Swiss mice strain. We found that administrating of CAPE (15. mg/kg S.C.) showed that the tumor volume decreased significantly by 51%. As a result, it improved animal chances of survival and they became healthier. An anti-angiogenic effect of CAPE in vivo was observed, as determined by a significant serum matrix metalloproteinase (MMP-9) reduction (142.1. ng/ml), activation of endostatin serum level (1.9. ng/ml), as well as DNA fragmentation in tumor treated mice when compared with untreated ones. Conclusion: CAPE has a significant inhibitory effect on tumor in vivo. This inhibition may be related to its angiostatic and apoptotic effects. It also reduced angiogenic factors which may shift the equilibrium to the angiostatic effect of CAPE. These findings provide the possibility for the future use of CAPE as tumor therapy in human clinical trials. � 2010 Elsevier Ireland Ltd.